Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort Angela S. ChengSamuel C. Y. LeungTorsten O. Nielsen Preclinical study Open access 14 September 2019 Pages: 3 - 10
Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy Clémence PinardMarc DebledGaëtan MacGrogan Preclinical study 16 September 2019 Pages: 11 - 23
High mobility group A1 (HMGA1) protein and gene expression correlate with ER-negativity and poor outcomes in breast cancer Mikhail GorbounovNeil M. CarletonLinda M. S. Resar Preclinical study 17 September 2019 Pages: 25 - 35
The intra-tumoural stroma in patients with breast cancer increases with age Kiki M. H. VangangeltClaire J. H. KramerWilma E. Mesker Preclinical study Open access 18 September 2019 Pages: 37 - 45
COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells Naoise C. SynnottDavid O’ConnellMichael J. Duffy Preclinical Study 19 September 2019 Pages: 47 - 56
Prevalence and scope of advanced practice provider oncology care among Medicare beneficiaries with breast cancer Tina W. F. YenPurushottam W. LaudAnn B. Nattinger Preclinical study 21 September 2019 Pages: 57 - 65
Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy Suzanne E. WardellAlexander P. YllanesDonald P. McDonnell Preclinical study Open access 27 September 2019 Pages: 67 - 77
The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer Abrar I. AljohaniMichael S. TossEmad A. Rakha Preclinical study Open access 10 October 2019 Pages: 79 - 90
Patient-reported outcomes and objective assessments with arm measurement and bioimpedance analysis for lymphedema among breast cancer survivors Mitsuo TeradaAkiyo YoshimuraHiroji Iwata Clinical trial 18 September 2019 Pages: 91 - 100
Pathological complete response to neoadjuvant systemic therapy in 789 early and locally advanced breast cancer patients: The Royal Marsden experience Nicolò Matteo Luca BattistiVictoria TrueAlistair Ring Clinical trial 18 September 2019 Pages: 101 - 111
A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases José Pablo LeoneDan G. DudaSara M. Tolaney Clinical trial 20 September 2019 Pages: 113 - 123
Factors associated with endometrial pathology during tamoxifen therapy in women with breast cancer: a retrospective analysis of 821 biopsies Jungeun JeonSung Eun KimDooSeok Choi Clinical trial 20 September 2019 Pages: 125 - 130
Correlation between patency and clinical improvement after lymphaticovenous anastomosis (LVA) in breast cancer-related lymphedema: 12-month follow-up Joost A. G. N. WolfsLuuke G. E. H. de JoodeShan S. Qiu Clinical trial Open access 21 September 2019 Pages: 131 - 138
Long-term prognostic effect of hormone receptor subtype on breast cancer Ki-Tae HwangJongjin KimSu-jin Kim Clinical trial 08 October 2019 Pages: 139 - 151
Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors Elena Gonzalez-RodriguezBérengère Aubry-RozierOlivier Lamy Clinical trial 09 October 2019 Pages: 153 - 159
A pooled analysis of the cardiac events in the trastuzumab adjuvant trials Evandro de AzambujaNoam PondeThomas Suter Clinical trial 11 October 2019 Pages: 161 - 171
Effect of progressive resistance training on persistent pain after axillary dissection in breast cancer: a randomized controlled trial Gunn AmmitzbøllKenneth Geving AndersenSusanne Oksbjerg Dalton Clinical trial 11 October 2019 Pages: 173 - 183
Bimodal age distribution at diagnosis in breast cancer persists across molecular and genomic classifications Emma H. AllottYue ShanMelissa A. Troester Epidemiology Open access 18 September 2019 Pages: 185 - 195
Research-based PAM50 signature and long-term breast cancer survival Minya PuKaren MesserLoki Natarajan Epidemiology Open access 21 September 2019 Pages: 197 - 206
Racial differences in employment and cost-management behaviors in patients with metastatic breast cancer Cleo A. SamuelJennifer C. SpencerStephanie B. Wheeler Epidemiology 25 September 2019 Pages: 207 - 215
Factors associated with endocrine therapy adherence among post-menopausal women treated for early-stage breast cancer in Ontario, Canada Phillip S. BlanchetteMelody LamCraig C. Earle Epidemiology 01 October 2019 Pages: 217 - 227
Distinct trajectories of fruits and vegetables, dietary fat, and alcohol intake following a breast cancer diagnosis: the Pathways Study Zaixing ShiAndrew RundleHeather Greenlee Epidemiology 10 October 2019 Pages: 229 - 240
Optimized immunohistochemical detection of estrogen receptor beta using two validated monoclonal antibodies confirms its expression in normal and malignant breast tissues John R. HawseJodi M. CarterMatthew P. Goetz Brief Report 30 September 2019 Pages: 241 - 249
Risk-reducing mastectomy in BRCA carriers: survival is not the issue P. NevenK. PunieE. Legius Letter to the Editor 20 September 2019 Pages: 251 - 252
Risk-reducing mastectomy in BRCA mutation carriers: survival is one of the issues—author's reply Bernadette Anna Maria Heemskerk-GerritsenMaartje Joanneke Hooning Rebuttal Letter 06 November 2019 Pages: 253 - 254
